Pamrevlumab (anti-CTGF)

目录号：A2042         批次号: A204204

打印

Pamrevlumab是一种与结缔组织生长因子(connective tissue growth factor, CTGF)结合的重组人源化抗体，已成为特发性肺纤维化(IPF)的潜在治疗方法。

抗体信息

CAS号 946415-13-0
配制 PBS Buffer, PH 7.4
推荐同型对照 Human IgG1, κ
应用 Pamrevlumab (anti-CTGF)
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 13.176mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Pamrevlumab (anti-CTGF)在文献中得到引用

Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling [ Circulation, 2025, Online ahead of print] PubMed: nan
Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer [ Cell Reports Medicine, 2025, 102480] PubMed: nan
[ Cell Commun Signal, 2024, ] PubMed: 38291510
ER stress-induced YAP upregulation leads to chondrocyte phenotype loss in age-related osteoarthritis [ Front Pharmacol, 2024, 15:1476255] PubMed: 39600372
ER stress-induced YAP upregulation leads to chondrocyte phenotype loss in age-related osteoarthritis [ Frontiers in Pharmacology, 2024, 1476255] PubMed: nan

禁止用于人体及治疗！